Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...